NCT05788926 - A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

TG6050

Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.

Trial Locations (5)

Hôpital Timone, Marseille

Institut Bergonié, Bordeaux

CHU Rennes - Hôpital Pontchaillou, Rennes

Institut de Cancérologie de l'Ouest, Saint-Herblain

Hôpital Européen Georges Pompidou, Paris